博雅生物
(300294)
| 流通市值:63.99亿 | | | 总市值:63.99亿 |
| 流通股本:5.04亿 | | | 总股本:5.04亿 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 846,914,941.7 | 643,555,888.03 | 321,128,375.86 | 2,059,088,027.17 |
| 营业收入 | 846,914,941.7 | 643,555,888.03 | 321,128,375.86 | 2,059,088,027.17 |
| 二、营业总成本 | 836,500,603.21 | 614,673,835.61 | 296,220,781.81 | 1,738,837,657.08 |
| 营业成本 | 482,972,407.13 | 359,063,537.9 | 172,563,810.33 | 1,031,721,835.18 |
| 税金及附加 | 12,751,310.26 | 10,002,055.49 | 5,071,317.57 | 19,374,755.99 |
| 销售费用 | 198,643,315.42 | 148,184,047.08 | 73,703,551.86 | 412,671,829.14 |
| 管理费用 | 147,491,844.37 | 103,289,144.66 | 50,714,378.77 | 239,178,310.56 |
| 研发费用 | 18,178,029.87 | 11,990,387.43 | 4,235,819.09 | 54,554,236.59 |
| 财务费用 | -23,536,303.84 | -17,855,336.95 | -10,068,095.81 | -18,663,310.38 |
| 其中:利息费用 | 1,875,623.89 | 1,247,412.3 | 631,044.98 | 1,161,725.54 |
| 其中:利息收入 | 11,768,964.18 | 8,339,954.6 | 4,073,006.41 | 13,615,107.1 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 20,785,470.47 | 10,444,438.13 | 6,725,948.97 | 59,977,597.95 |
| 加:投资收益 | -32,105,155.72 | -34,436,670.69 | 3,933,274.5 | 23,806,314.16 |
| 资产处置收益 | -528,699.72 | -394,883.47 | -348,365.67 | 5,095,324.42 |
| 资产减值损失(新) | -160,000.57 | -156,560.68 | -155,939.71 | -316,529,570.79 |
| 信用减值损失(新) | 5,818,381.56 | -4,720,502.68 | -1,582,061.29 | -23,652,590.17 |
| 其他收益 | 7,574,952.46 | 5,842,568.1 | 3,667,173.74 | 40,474,982.72 |
| 四、营业利润 | 11,799,286.97 | 5,460,441.13 | 37,147,624.59 | 109,422,428.38 |
| 加:营业外收入 | 716,877 | 683,778.51 | 143,120.15 | 3,023,017.98 |
| 减:营业外支出 | 11,715,310.74 | 2,718,184.21 | 1,287,236.19 | 8,566,951.28 |
| 五、利润总额 | 800,853.23 | 3,426,035.43 | 36,003,508.55 | 103,878,495.08 |
| 减:所得税费用 | -59,787,411.6 | -47,458,848.1 | 5,970,116.3 | -8,760,276.94 |
| 六、净利润 | 60,588,264.83 | 50,884,883.53 | 30,033,392.25 | 112,638,772.02 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 33,692,910.13 | 23,989,528.83 | 30,033,392.25 | 112,638,772.02 |
| 终止经营净利润 | 26,895,354.7 | 26,895,354.7 | - | - |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 62,337,285.72 | 51,188,692.08 | 30,220,896.06 | 112,698,348.56 |
| 少数股东损益 | -1,749,020.89 | -303,808.55 | -187,503.81 | -59,576.54 |
| 扣除非经常损益后的净利润 | 30,136,840.55 | 17,151,386.51 | 20,323,474.32 | -7,757,477.26 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.12 | 0.1 | 0.06 | 0.22 |
| (二)稀释每股收益 | 0.12 | 0.1 | 0.06 | 0.22 |
| 八、其他综合收益 | -13,172,038.35 | -10,184,885.93 | -5,943,787.21 | -5,885,761.41 |
| 归属于母公司股东的其他综合收益 | -13,172,038.35 | -10,184,885.93 | -5,943,787.21 | -5,885,761.41 |
| 九、综合收益总额 | 47,416,226.48 | 40,699,997.6 | 24,089,605.04 | 106,753,010.61 |
| 归属于母公司股东的综合收益总额 | 49,165,247.37 | 41,003,806.15 | 24,277,108.85 | 106,812,587.15 |
| 归属于少数股东的综合收益总额 | -1,749,020.89 | -303,808.55 | -187,503.81 | -59,576.54 |
| 公告日期 | 2026-10-30 | 2026-08-22 | 2026-04-25 | 2026-03-21 |
| 审计意见(境内) | | | | 标准无保留意见 |